CLINICAL BEHAVIOR OF BORDERLINE OVARIAN-TUMORS - A STUDY OF 150 CASES

Background: We evaluated the clinical features, treatment, and surviva l status of the patients with borderline ovarian tumors. Methods: A re trospective review of the charts of 150 patients with borderline ovari an tumor registered at the Tokai Ovarian Tumor Study Group from Januar y 1, 1980, to December 31, 1994, was conducted to obtain clinical and pathological information. Results: In stage II and III disease, the nu mbers of patients with no residual tumor, residual tumor of <2 cm, 2-5 cm, and >5 cm were 9, 10, 3, and 3, respectively. The sizes of residu al tumors and corresponding clinical response to chemotherapy were as follows: residual tumor of <2 cm, complete response (CR), 6 patients; no change (NC), 2; progressive disease (PD), 2; tumors 2-5 cm, NC, 1 p atient, PD, 2; tumors >5 cm, PD, 3 patients. The survival for patients with residual tumor <2 cm was significantly better than for those wit h residual tumor from 2-5 cm and of >5 cm (P < 0.05). The survival for patients with stage II and III serous tumor was significantly longer than that for patients with stage II and III mucinous tumor (P < 0.05) . Conclusion: In advanced borderline ovarian tumor, the prognosis of p atients with gross residual tumor after initial surgery, and especiall y with mucinous tumor, was poor. (C) 1997 Wiley-Liss, Inc.